News

The fundraise was co-led by new investors OrbiMed Advisors and Arix Bioscience plc and included investment from RA Capital and Rock Springs Capital. Existing investors New Enterprise Associates,

Extensive blistering can lead to serious, life-threatening fluid loss, infection and/or death. MabThera is the first biologic therapy approved by the European Commission for PV and the first

Based in Tokyo, Ayumi is engaged in the manufacturing and marketing of various drug products for anti-rheumatism and orthopedic pain management. Citing a person familiar with the matter,

The findings of the study, called European Sudden Cardiac Arrest network (ESCAPE-NET), were presented at European Heart Rhythm Association (EHRA) 2019. It evaluated if nifedipine and amlodipine –

Hereditary Spinocerebellar Ataxias are rare, potentially fatal neurodegenerative disorders affecting the cerebellum. They are characterized clinically by progressive ataxia symptoms, including difficulties with balance, speech, and coordination, and

Under The collaboration agreement will enable Merck to use Iktos generative modelling AI technology to facilitate the rapid and cost-effective discovery and design of new compounds. The agreement

“Many individuals with diabetes treated with insulin experience EIH and the complexity of managing it is a major barrier to the adoption of regular physical activity. And unfortunately,

Hemlibra can be used in all age groups, and can also now be used at multiple dosing options (once weekly, every two weeks, or every four weeks) for

Esperion said that bempedoic acid is under development as a complementary, cost-effective, once-daily and oral therapy to treat patients with elevated LDL-C. The company has submitted new drug